Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Drug Metabolism and Personalized Therapy is Scopus-indexed (Q2, CiteScore 3.2). Published by Walter de Gruyter GmbH.
Checked against the index lists dated .
ISSN 2363-8907Verify ISSN ↗2363-8915Verify ISSN ↗
Publisher: Walter de Gruyter GmbH
Cost to publish: About US$2,712 to publish open access (publisher list price, via OpenAlex) — subscription publishing may be free
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Pharmacology, Toxicology and Pharmaceutics (all) | 30 / 79 | 62nd | Q2 |
| Pharmacology (medical) | 158 / 278 | 43rd | Q3 |
Not listed in: Web of Science, DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2015–present, best quartile Q2, CiteScore 3.2.
Drug Metabolism and Personalized Therapy is Q2 in Pharmacology, Toxicology and Pharmaceutics (all) (rank 30 of 79) and Q3 in Pharmacology (medical) (rank 158 of 278), by CiteScore 2025.
Drug Metabolism and Personalized Therapy is not in the Web of Science Core Collection (SCIE, SSCI, AHCI or ESCI), so Clarivate publishes no Journal Impact Factor for it. Its Scopus CiteScore is 3.2, quartile Q2, 62nd percentile. Any "impact factor" quoted elsewhere is not the Clarivate metric. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.322, quartile Q2, with an H-index of 41.
The publisher lists an article processing charge of about US$2,712 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Drug Metabolism and Personalized Therapy is published by Walter de Gruyter GmbH. Its print ISSN is 2363-8907 and its online ISSN is 2363-8915.
No — it is not currently in the Web of Science core collections (SCIE, SSCI, AHCI or ESCI).
No — it is not registered as an open-access journal in DOAJ or Scopus.
Drug Metabolism and Personalized Therapy has an h-index of 22 and a 2-year mean of 2.16 citations per paper (OpenAlex). Its Scopus CiteScore is 3.2, quartile Q2. On 2-year citations it ranks #28 of 77 Scopus journals in Pharmacology, Toxicology and Pharmaceutics (all).
Drug Metabolism and Personalized Therapy published 28 papers in 2025; its busiest recent year was 2021 with 77. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 93 research articles (2023–2026), authors are most often from India (30.6%), Russia (9.1%) and Jordan (8.1%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. No retracted papers are recorded. The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.